Full-Time

Account Manager

Confirmed live in the last 24 hours

Schrödinger

Schrödinger

501-1,000 employees

Computational platform for biopharmaceutical research

Government & Public Sector
Enterprise Software
Biotechnology

Mid

United Kingdom

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Experience in account management, business development, or consulting in the chemical and/or pharmaceutical industries
  • Advanced degree in life sciences (knowledge of materials science or molecular modeling is a plus)
  • Some familiarity with computational chemistry software
  • Fluency in English
Responsibilities
  • Identify, qualify, and develop new business in relation to biotech, pharmaceuticals, and life science sectors
  • Manage and grow existing accounts
  • Collaborate with the EU+ team to develop business and marketing strategies to target specific customer segments
  • Produce timely and accurate business reports and revenue forecasts
  • Travel to customers and conferences

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and research across various therapeutic areas. Schrödinger's products work by utilizing sophisticated algorithms and simulations to predict molecular behavior, which assists researchers in understanding how different compounds can affect biological systems. What sets Schrödinger apart from its competitors is its extensive global reach, serving clients in over 70 countries, and its dual focus on both software licensing and collaborative drug discovery programs. The company's goal is to advance scientific research and innovation by providing powerful tools and services that enhance the drug discovery process.

Company Stage

IPO

Total Funding

$362.7M

Headquarters

New York City, New York

Founded

1990

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • $19.5M Gates Foundation grant boosts research in neglected diseases, expanding R&D opportunities.
  • $10M grant supports predictive toxicology tools, reducing drug development failures.
  • Schrödinger's platform efficiently explores chemical space, accelerating drug candidate identification.

What critics are saying

  • Recursion and Exscientia merger creates a strong competitor in AI-driven drug discovery.
  • Avicenna's independent expansion could lead to competitive tensions with Schrödinger.
  • Reliance on grants like Gates Foundation funding poses financial sustainability risks.

What makes Schrödinger unique

  • Schrödinger's platform supports diverse clients, including biopharmaceuticals and academic institutions globally.
  • The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.
  • Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.

Help us improve and share your feedback! Did you find this helpful?